(Q37008623)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

review article

1 reference

title

Alpha-v integrins as therapeutic targets in oncology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Jeffrey A Nemeth

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Marian T Nakada

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

M Trikha

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Zhihui Lang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Michael S Gordon

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Robert Corringham

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Uma Prabhakar

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Hugh M Davis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Robert A Beckman

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

1 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

632-646

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

Role of integrins in cancer: survey of expression patterns

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Function and interactions of integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Get a ligand, get a life: integrins, signaling and cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

The role of integrins in human embryo implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Role of integrins in cell invasion and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Ligand binding to integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

The alpha v integrin antagonists as novel anticancer agents: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Integrin signalling during tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Fundamental Concepts of the Angiogenic Process

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Overview of angiogenesis: Biologic implications for antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

A reevaluation of integrins as regulators of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

The diverse roles of integrins and their ligands in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Integrins, angiogenesis and vascular cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Integrins and oral cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Binding of TGF-beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Differential gene expression in ovarian carcinoma: identification of potential biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

VEGF-integrin interplay controls tumor growth and vascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Integrin and growth factor receptor crosstalk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

21 January 2018

Inhibitors of integrins

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Integrin adhesion receptors in tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Treatment of adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Treatment options for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Antiangiogenic therapy at a crossroads: clinical trial results and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Promises and pitfalls of anti-angiogenic therapy in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Challenges for imaging angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Key factors in the acquisition of contrast kinetic data for oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Nuclear magnetic resonance spectroscopy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

PET for in vivo pharmacokinetic and pharmacodynamic measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Positron emission tomography: a new investigational area for cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Multimodality tumor imaging targeting integrin alphavbeta3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Apoptosis of circulating tumor cells in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

ArgGlyAsp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts*1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Development of target-based antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Multinomial phase II cancer trials incorporating response and early progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Trastuzumab: hopes and realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Current perspectives on HER2 testing: a review of national testing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

HER2: the neu prognostic marker for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Expanding the clinical development of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

A new colloidal lipidic system for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Nanoparticle-mediated gene delivery to tumour neovasculature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

Integrin β4 signaling promotes tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522638

10.1080/07357900701522638

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18027153%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference